Viewing Study NCT00522457

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:44 PM
Ignite Modification Date: 2026-02-24 @ 2:07 PM
Study NCT ID: NCT00522457
Status: TERMINATED
Last Update Posted: 2011-04-29
First Post: 2007-08-28
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
Sponsor: Neovii Biotech
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Breast Cancer View
None Advanced Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast Cancer View
None investigational drug View
None drug therapy View
None Antineoplastic Protocols View
None Immunotherapy View
None Metastatic breast cancer View
None Advanced breast cancer View
None Stage IV breast cancer View
None Her-2/neu expressing breast cancer View
None Her-2/neu View
None Trastuzumab refractory View